Janssen R&D announced results from a Phase 3 study on the use of initial combination therapy of canagliflozin and metformin extended release (XR) in type 2 diabetes patients with higher A1C levels and who treat their type 2 diabetes with diet and exercise only. The findings were presented at the 75th American Diabetes Association (ADA) Scientific Sessions in Boston, MA.
In the 26-week study, 1,186 patients with type 2 diabetes and inadequate hemoglobin A1c (HbA1C) control despite treatment with diet and exercise were randomized to receive canagliflozin 100mg in combination with metformin XR (median 2,000mg/day), canagliflozin 300mg in combination with metformin XR, canagliflozin 100mg, canagliflozin 300mg, or metformin XR. Comparisons of canagliflozin to metformin were also evaluated.
Both groups receiving canagliflozin plus metformin XR had statistically superior HbA1C reductions (-1.77 and -1.78, respectively) vs. patients receiving either canagliflozin 100mg (-1.30), 300mg (-1.37) , or metformin XR (-1.42) alone. Patients taking canagliflozin in combination with metformin XR also had a significant reduction in weight compared to patients treated with metformin XR alone.
For more information visit JanssenRND.com.